Angewandte Chemie International Edition · 2021 · 37 citations · 27 references
MedicineImmunologyOncologyCancer ImmunologyImmunizationVaccinologyAntigen DesignCancer VaccinesConjugate VaccinesTumor-associated AntigensVaccine Antigen DesignVaccine Antigen DiscoveryAntibodiesAntibody ImmunogenicityCarbohydrate Antigen DesignCarbohydrate Antigen TargetingGlycan-based ConjugationGlycoconjugate Vaccine DesignRecombinant Antibody ConjugatesTumor-associated Carbohydrate Antigens
Ganglioside GD2 is an attractive tumor-associated carbohydrate antigen for anti-cancer vaccine development. However, its low immunogenicity and the significant side effects observed with anti-GD2 antibodies present significant obstacles for vaccines. To overcome these, a new GD2 derivative bearing an N-acetamide (NHAc) at its non-reducing end neuraminic acid (9NHAc-GD2) has been designed to mimic the 9-O-acetylated-GD2 (9OAc-GD2), a GD2 based antigen with a restricted expression on tumor cells. 9NHAc-GD2 was synthesized efficiently via a chemoenzymatic method and subsequently conjugated with a powerful carrier bacteriophage Qβ. Mouse immunization with the Qβ-9NHAc-GD2 conjugate elicited strong and long-lasting IgG antibodies, which were highly selective toward 9NHAc-GD2 with little cross-recognition of GD2. Immunization of canines with Qβ-9NHAc-GD2 showed the construct was immunogenic in canines with little adverse effects, paving the way for future clinical translation to humans.
27
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
Erika Vacchelli, Lorenzo Galluzzi, Alexander Eggermont et al. · OncoImmunology · 2012 · 245 citations · Full text
Hai Yu, Hui Yu, Rebekah Karpel et al. · Bioorganic & Medicinal Chemistry · 2004 · 242 citations